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Abstract
Background:  Methicillin resistant Staphylococcus aureus (MRSA) is the leading pathogenic cause of
nosocomial infections, especially in bacteraemia and sepsis. The essential therapy for MRSA infection is
glycopeptides. Therapeutic failure can be seen with this therapy and the mortality is still high. The aim of
this study was to evaluate the additional effect of G-CSF on the traditional antibiotic treatment in an
experimental MRSA sepsis.
Methods: Experimental sepsis was performed in mice by intraperitoneal injection of MRSA isolate.
Inoculum dose was estimated as 6 × 109/ml. Mice were randomised for the study into four group; control
group (not receive any therapy), G-CSF group (1000 ng/daily, subcutaneously for 3 d), antibiotic group
(vancomycin 25 or 50 mg/kg intraperitoneally every 12 hours for 7 d), and vancomycin+G-CSF group (at
the same concentrations and duration). Autopsy was done within one hour after mice died. If mice was
still alive at the end of seventh day, they were sacrificed, and autopsy was done. In all groups, the effect of
G-CSF therapy on the survival, the number of the MRSA colonies in the lung, liver, heart, spleen, and
peritoneal cultures, the histopathology of the lung, liver, heart and spleen was investigated.
Results: One hundred and six mice were used. There were no significant differences in survival rates and
bacterial eradication in G-CSF group compared with control group, and also in antibiotic +G-CSF group
compared with antibiotic alone group. These parameters were all significantly different in antibiotic alone
group compared with control group. Histopathologically, inflammation of the lung and liver were
significantly reduced in vancomycin (25 mg/kg)+G-CSF and vancomycin (50 mg/kg)+G-CSF subgroups,
respectively (p < 0.01). The histopathological inflammation of the other organs was not significantly
different in antibiotic+G-CSF group compared with antibiotic group and, also G-CSF group compared with
control group.
Conclusion: G-CSF treatment had no additional effect on survival and bacterial eradication in MRSA
sepsis in nonneutropenic mice; and only a little effect on histopathology. G-CSF treatment is very
expensive, likewise glycopeptides. The more interest in infection control measures, and prevent the
spread of MRSA infections is more rational.
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Background
Staphylococcus aureus is an extremely virulent pathogen,
and causes serious and deep-seated infections (e.g. endo-
carditis, osteomyelitis) [1]. In recent years, S. aureus is the
leading pathogenic cause of both community-acquired
and nosocomial infections, especially in bacteremia and
sepsis [2-4]. Despite advances in antistaphylococcal
drugs, S. aureus sepsis is one of the most important causes
of death [5]. Furthermore, methicillin resistant strains are
increasing in community and hospitals during the past
decades, and many investigators proposed methicillin
resistance as an independent predictor of adverse out-
come [6,7]. The essential therapy for methicillin resistant
S. aureus (MRSA) infections is glycopeptides (vancomycin
or teicoplanin). However glycopeptides are intrinsically
less effective against staphylococci than are antistaphyloc-
cal β-lactams [1]. This may explain therapeutic failure and
high mortality of MRSA infections.
Advances in the pathophysiology of sepsis and septic
shock suggest new therapeutic agents and approaches.
Granulocyte-colony stimulating factor (G-CSF), a potent
stimulator of neutrophil counts and functions, is one of
these new strategies in sepsis. Despite a number of studies
in sepsis, especially in neonatal sepsis, clinical efficacy of
G-CSF is still controversial [8].
The aim of this experimental study was to evaluate the
role of G-CSF in the treatment of MRSA sepsis.
Methods
Animal care and use
Male BALB-C mice (8–10 weeks old, weighing 20–25 g)
were obtained from Erciyes University Hakan Cetinsaya
Experimental and Clinical Research Center. The Animal
Care Committee of Erciyes University approved the exper-
imental protocol used in this study. The animals were kept
in a cage and allowed to feed and drink water.
Bacterial strain
The clinical MRSA isolate, obtained from a patient's blood
and pleural effusion admitted in General Surgical Inten-
sive Care Unit of Erciyes University with nosocomial sep-
sis, was used. The strain was subcultured on blood agar at
37°C over night. On the day of experiment, bacterial sus-
pension was prepared by sodium chloride 0.9% solution
and the concentration was adjusted by spectrophotome-
ter. The bacterial account needed for experimental sepsis
was determined by a fore study. The fore study was begun
with the inoculum dose of 1 × 107/ml bacterial suspen-
sion and gradually increased until experimental sepsis
developed. Experimental sepsis was defined as the growth
of MRSA in two or more organs. The inoculum dose of
this study was estimated as 6 × 109/mL.
Treatment
First dose of antibiotic was given at the sixth hour of bac-
terial inoculation. Vancomycin (DBL, 500 mg flacon),
diluted in 5% dextrose, was given at 25 mg/kg or 50 mg/
kg concentrations intraperitoneally every 12 hours for 7
days. rhG-CSF (Roche, Neupogen flk 30 mu/ 1 mL),
diluted in 5% dextrose, was received 1000 ng/daily subcu-
taneously for 3 days [9].
Study design
Animals were randomised to four groups; control group,
G-CSF group, vancomycin group, and vancomycin +G-
CSF group. The last two groups were divided into two sub-
groups for different dosage of vancomycin (25 mg/kg or
50 mg/kg). Each group had at least 15 mice and were kept
in different cage. In control group, only bacteria suspen-
sion was given and no treatment was received.
Bacterial suspension was given intraperitoneally to the
mice, and when mice died, autopsy was done within one
hour in aseptic conditions. If the mice was still alive at the
end of seventh day, mice were sacrificed by servical dislo-
cation and autopsy was done. The samples were taken
from lung, liver, heart, spleen, and peritoneum for micro-
biological investigation, and from lung, liver, heart and
spleen for histopathological examination. In each group,
survival days were noted.
Samples were taken from the organs with swab by one
rotation on its axis, and were cultured on blood agar over
night. The colonies on the agar were counted. The colo-
nies more than 300 cfu in a plate noted as >300 cfu.
The same pathologist examined tissue samples stained
with hematoxylin and eosin. The degree of inflammation
was graded by on a scale of 0 to ++++ (0, no inflamma-
tion; focal interstitial inflammation +; more diffuse inter-
stitial inflammation ++; intense interstitial inflammation
or microabscesses +++; more extensive abscess formation
with tissue necrosis ++++) [10]. The pathologist was una-
ware about the groups.
Survival days, semiquantitative bacterial count and his-
topathologic findings in the tissues of the treatment
groups were compared with the control group.
Statistics
Survival was assessed using a log-rank test. Fisher's extract
test and chi-square test were used to compare the groups.
Mann Whitney U test was used to compare the histopa-
thology. A p value less than 0.05 was considered
significant.BMC Infectious Diseases 2004, 4:43 http://www.biomedcentral.com/1471-2334/4/43
Page 3 of 8
(page number not for citation purposes)
Results
This study included 110 mice. Three mice that developed
intraabdominal hemorrhage, and one mouse that devel-
oped Esherichia coli sepsis were excluded. 106 mice were
evaluated. Six mice in control group, six mice in G-CSF
group, 15 mice in vancomycin 25 mg, 15 mice in vanco-
mycin 25 mg+G-CSF group, 18 mice in vancomycin 50
mg group and 14 mice in vancomycin 50 mg+G-CSF
group were sacrificed at the end of seventh day. The death
day and the survival rate of the mice in the groups are
shown by the survival curve in figure 1,2,3. The compari-
son of the groups between G-CSF and control, vancomy-
cin (25 mg/kg) and vancomycin (25 mg/kg)+G-CSF,
vancomycin (50 mg/kg) and vancomycin (50 mg/kg)+G-
CSF showed no differences (p >0.05).
Culture and histopathology results are shown in Table 1.
Antibiotic administration decreased bacterial count, and
decreased inflammation rate in the organs. Culture and
histopathological results in control and G-CSF group were
not statistically different (p > 0.05). However, all these
parameters were significantly different in antibiotic
groups compared with control group (p < 0.01). Cultures
of the organs in antibiotic groups were not statistically dif-
ferent from antibiotic+G-CSF group (p > 0.05). Only the
inflammation degree in the lung and the liver were
Proportion of animals surviving after inoculation with MRSA in control and G-CSF groups Figure 1
Proportion of animals surviving after inoculation with MRSA in control and G-CSF groups.BMC Infectious Diseases 2004, 4:43 http://www.biomedcentral.com/1471-2334/4/43
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significantly reduced in vancomycin (25 mg/kg)+G-CSF
group and vancomycin (50 mg/kg)+G-CSF group, respec-
tively (p < 0.01). The inflammatory changes were not sig-
nificantly reduced in the other organs in two groups (p >
0.05).
Discussion
In recent years, MRSA has become widespread around the
world, and become highly endemic in some hospitals. In
the United States, the proportion of MRSA isolates
increased from 2.4% in 1975 to up to 55% in recent years
[11,12]. Similarly, in Europe the resistance rates increased
from 12.8% to 26.3% [12,13]. Also, it is extremely high
(>60%) in some regions of the world [12]. The recent
studies, conducted in our hospital, showed 66% methicil-
lin resistance in nosocomial S. aureus strains, isolated
from the bloodstream infections [2,14]. Unfortunately,
community-acquired MRSA also increases during the past
decades [15].
G-CSF is a cytokine that stimulates myeloid progenitor
cell proliferation and increases the bone marrow storage
pool and the number of circulating mature neutrophils,
which are important component of the host defense [16].
Also, it enhances neutrophil activities (chemotaxis,
phagocytosis, antibody-mediated cytotoxicity, etc.) [17].
Proportion of animals surviving after inoculation with MRSA in vancomycin 25 mg/kg and vancomycin 25 mg/kg+G-CSF groups Figure 2
Proportion of animals surviving after inoculation with MRSA in vancomycin 25 mg/kg and vancomycin 25 mg/kg+G-CSF groups
Day after inoculation
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An inappropriate endogenous G-CSF response may be
associated with an adverse outcome to sepsis. Low serum
G-CSF concentrations (0 to 125 pg/mL) on admission are
supposed to be associated with fatal outcome in patients
with bacterial infections [18]. Investigators proposed to
use G-CSF in infections in which neutrophil number and
function are important to resolution and survival, also in
patients which may have reduced neutrophil numbers or
function because of underlying disease or physiologic
state. The low toxicity and the beneficial effect on survival
in animal studies have led to several clinical trials of rhG-
CSF as an adjuvant therapy in treatment of infection in
nonneutropenic patients [19,20]. Its beneficial effect was
shown in clinical studies in diabetic foot infections,
wound infections, extensive burns and fungal infections
[21-23]. Also neutrophils in sepsis demonstrate a number
of functional abnormalities (e.g. reduced bacterial killing,
superoxide production, and migration) [24] and it can be
hypothesized that these abnormalities can be corrected
with G-CSF.
The previous experimental therapeutic studies were
mostly carried out in gram-negative sepsis, and in this
experimental study, we investigated the effect of G-CSF in
MRSA sepsis. The survival rates were not significantly dif-
ferent in G-CSF group compared with the control group,
and also in antibiotic+G-CSF group compared with anti-
biotic alone group. Likewise, most of the other
Proportion of animals surviving after inoculation with MRSA in vancomycin 50 mg/kg and vancomycin 50 mg/kg+G-CSF groups Figure 3
Proportion of animals surviving after inoculation with MRSA in vancomycin 50 mg/kg and vancomycin 50 mg/kg+G-CSF groups
Day after inoculation
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experimental studies in gram negative sepsis, showed that
prophylactic rhG-CSF administration reduced endotox-
emia and serum TNF-α levels and also improved cardiac
function and survival, whereas therapeutic rhG-CSF (i.e.
administered after the onset of infection) did not improve
outcome and at very high dosages appeared harmful
[25,26]. A recent multicenter, double-blind, randomised
and placebo controlled study in patients hospitalised with
pneumonia and severe sepsis, demonstrated that G-CSF
had no beneficial effect in reducing mortality rates or
complications from severe sepsis [27].
Table 1: Cultures and histopathology of study groups
Control G-CSF Vanco – 25 mg Vanco 25 mg + 
G-CSF
Vanco – 50 mg Vanco – 50 mg + 
G-CSF
nn n n n n
Mice 15 15 15 15 24 22
Cultures Lung
no growth - 1 15 15 18 14
<300 cfu - 3 - - - -
>300 cfu 15 11 - - 6 8
Liver
no growth - 1 15 15 17 14
<300 cfu - 2 - - 1 -
>300 cfu 15 12 - - 6 8
Heart
no growth - 1 15 15 18 14
<300 cfu - 3 - - - -
>300 cfu 15 11 - - 6 8
Spleen
n o  g r o w t h--1 3 1 5 1 3 1 2
<300 cfu - 1 - - 3 2
>300 cfu 15 14 2 - 8 8
Periton
no growth - 2 15 15 17 13
<300 cfu - 1 - - 1 1
>300 cfu 15 12 - - 6 8
Histopathology 
(inflammation degree)
Lung
0 000 0 0 0
+ 215 1 7 9
+ + 767 6 9 9
+++ 5 7 3 7 8 4
++++ 1 1 0 1 0 0
Liver
0 000 1 1 0
+ 147 5 1 2 5
+ + 724 5 9 1 0
+++ 4 6 4 4 2 7
++++ 3 3 0 0 0 0
Heart
0 108 8 1 0 1 0
+ 9 11 7 6 12 7
+ + 520 1 0 5
+++ 0 0 0 0 0 0
++++ 0 0 0 0 0 0
Spleen
0 010 0 1 1
+ 027 5 1 3 8
+ + 547 6 7 8
+++ 4 6 1 4 2 5
++++ 6 2 0 0 1 0
Inflammation degree No inflammation 0
Focal interstitial inflammation +
More diffüse interstitial inflammation ++
Intense interstitial inflammation veya microabscesses +++
More extensive abscess formation with tissue necrosis ++++BMC Infectious Diseases 2004, 4:43 http://www.biomedcentral.com/1471-2334/4/43
Page 7 of 8
(page number not for citation purposes)
In this study, we did not measure the WBC count, so not
have subgroups with neutropenia. In an experimental
gram-negative sepsis in rabbits, Smith and colleguaes [28]
showed the beneficial effect of therapeutic rhG-CSF only
in early sepsis due to gram negative bacteria when compli-
cated by leukopenia, no significant difference in nonneu-
tropenic group.
Bacteria are rapidly cleared from blood and tissues follow-
ing intravenous antibiotic therapy [10]. In our study, anti-
biotic received group had significantly low bacterial count
in the organ cultures compared with the other groups,
however G-CSF had no beneficial effect on the bacterial
clearance.
The histopathologic findings of invasive S. aureus infec-
tions are leukocytic infiltration, focal pneumonitis,
edema, microabscesses, etc. In an experimental study, sig-
nificant pathologic changes during and after the elimina-
tion of bacteria from the blood and tissues were noted.
Also, expression of cytokines (TNF, IL-1, IL-6) was
observed in all of the infected tissues, and correlated tissue
damage after clearance of bacteria from the blood and tis-
sues[10]. However, in our study, G-CSF significantly
reduced only the inflammation in the lung and liver in
vancomycin +G-CSF subgroups (p < 0.01). This effect of
G-CSF could not be explained. There was no significant
effect of G-CSF on the other organs inflammation.
In conclusion, G-CSF treatment had no additional effect
on survival and bacterial eradication in MRSA sepsis in
nonneutropenic mice; and only a little effect on histopa-
thology. Furthermore, G-CSF treatment is very expensive,
likewise glycopeptides. Because of high mortality and
morbidity rates and excess costs, more interest in infection
control measures, and prevent the spread of MRSA infec-
tions is more rational.
Competing interests
This study was supported by Erciyes University Research
Fund. There was no non-financial competing interest.
Authors' contributions
EA and SG were the primary researchers. OC and BK are
the pathologist and examined tissue samples. MD was the
director of the study. All authors read and approved the
final manuscript.
References
1. Waldvogel FA: Staphylococcus aureus (including staphylococcal
toxic shock). In: Principles and practise of infectious diseases fifth edi-
tion. Edited by: Mandell GL, Bennett JE, Dolin R. Churchill Livingstone,
Philadelphia; 2000:2069-2092. 
2. Esel , Doganay M, Alp E, Sumerkan B: Prospective evaluation of
blood cultures in a Turkish university hospital: epidemiology,
microbiology and patient outcome. Clin Microbiol Infect 2003,
9:1038-1044.
3. Wisplinghoff H, Seifert H, Tallent SM, Bischoff T, Wenzel RP, Edmond
MB: Nosocomial bloodstream infections in pediatric patients
in United States hospitals: epidemiology, clinical features
and susceptibilities. Pediatr infect Dis J 2003, 22:686-691.
4. Mylotte JM, Tayara A, Goodnough S: Epidemiology of blood-
stream infection in nursing home residents:evaluation in a
large cohort from multiple homes.  Clin Infect Dis 2002,
35:1484-1490.
5. Lautenschlager S, Herzog C, Zimmerli W: Course and outcome of
bacteremia due to Staphylococcus aureus : evaluation of dif-
ferent clinical case definitions. Clin Infect Dis 1993, 16:567-573.
6. Conterno LO, Wey SB, Castelo A: Risk factors for mortality in
Staphylococcus aureus bacteremia. Infect Control Hosp Epidemiol
1998, 19:32-37.
7. Harbarth S, Rutschmann O, Sudre P, Pittet D: Impact of methicillin
resistance on the outcome of patients with bacteremia
caused by Staphylococcus aureus.  Arch Intern Med 1998,
158:182-189.
8. Dale DC, Liles C, Summer WR, Nelson S: Review: granulocyte
colony-stimulating factor-role and relationships in infectious
diseases. J Infect Dis 1995, 172:1061-1075.
9. O'Reilly M, Silver GM, Greenhalgh DG, Gamelli RL, Davis JH, Hebert
JC: Treatment of intra-abdominal infection with granulocyte
colony-stimulating factor. J Trauma 1992, 33:679-682.
1 0 . Y a o  L ,  B e r m a n  J W ,  F a c t o r  S M ,  L o w y  F D :  Correlation of his-
topathologic and bacteriologic changes with cytokine
expression in an experimental murine model of bacteremic
Staphylococcus aureus infection.  Infect Immun 1997,
65:3889-3895.
11. Panlilio AL, Culver DH, Gaynes RP, Banerjee S, Henderson TS, Tol-
son JS, Martone WJ: Methicillin resistant Staphylococcus aureus
in US hospitals, 1975–1991. Infect Control Hosp Epidemiol 1992,
13:582-586.
12. Diekema DJ, Pfaller MA, Schmitz FJ, Smayevsky J, Bell J, Jones RN,
Beach M: SENTRY Partcipants Group. Survey of infections
due to Staphylococcus species: frequency of occurrence and
antimicrobial susceptibility of isolates collected in the
United States, Canada, Latin America, Europe, and the
Western Pacific region for the SENTRY antimicrobial sur-
veillance program, 1997–1999. Clin Infect Dis 2001, 32(Suppl
2):S114-32.
13. Voss A, Milatovic D, Wallrauch-Schwarz C, Rosdahl VT, Braveny I:
Methicillin-resistant Staphylococcus aureus in Europe. Eur J Clin
Microbiol Infect Dis 1994, 13:50-55.
14. Aygen B, Yoruk A, Yyldyz O, Alp E, Kocagoz S, Sumerkan B, Doganay
M: Bloodstream infections caused by Staphylococcus aureus in
a university hospital in Turkey: clinical and molecular epide-
miology of methicillin-resistant Staphylococcus aureus.  Clin
Microb Infect 2004, 10:309-314.
15. Kallen A, Driscoll T, Thornton S, Olson P, Wallace M: Increase in
community-acquired methicillin-resistant  Staphylococcus
aureus at a Naval Medical Center. Infect Control Hosp Epidemiol
2000, 21:223-226.
16. Gillan ER, Christensen RD, Suen Y, Ellis R, Ven C, van de, Cairo MS:
A randomized, placebo-controlled trial of recombinant
human granulocyte colony-stimulating factor administration
in newborn infants with presumed sepsis: significant induc-
tion of peripheral and bone marrow neutrophilia. Blood 1994,
84:1427-1433.
17. Hustinx W, Benaissa-Trouw B, Van Kessel K, Kuenen J, Tavares L,
Kraaijeveld K, Verhoef J, Hoepelman A: Granulocyte colony-stim-
ulating factor enhances protection by anti-K1 capsular IgM
antibody in murine Escherichia coli sepsis. Eur J Clin Invest 1997,
27:1044-1048.
18. Weiss M, Moldawer LL, Schneider EM: Granulocyte Colony-Stim-
ulating factor to prevent the progression of systemic nonre-
sponsiveness in systemic inflammatory response syndrome
and sepsis. Blood 1999, 93:425-439.
19. Wunderink R, Leeper K Jr, Schein R, Nelson S, DeBoisblanc B, Foth-
eringham N, Logan E: Filgrastim in patients with pneumonia
and severe sepsis or septic shock. Chest 2001, 119:523-529.
20. Bedford Russell AR, Emmerson AJ, Wilkinson N, Chant T, Sweet DG,
Halliday HL, Holland B, Davies EG: A trial of recombinant human
granulocyte colony stimulating factor for the treatment of
very low birthweight infants with presumed sepsis and
neutropenia. Arch Dis Child Fetal Neonatal Ed 2001, 84:F172-F176.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Infectious Diseases 2004, 4:43 http://www.biomedcentral.com/1471-2334/4/43
Page 8 of 8
(page number not for citation purposes)
21. Gough A, Clapperton M, Rolando N, Foster AV, Philpott-Howard J,
Edmonds ME: Randomised placebo-controlled trial of granulo-
cyte-colony stimulating factor in diabetic foot infection. Lan-
cet 1997, 350:855-859.
22. van Linert ACM, Sijmons EA, Damen BFM, Heintz APM: Wound
healing after radical vulvectomy and inguino-femoral lym-
phadenectomy: experience with granulocyte colony stimu-
lating factor (filgrastim rmetHuG-CSF). Eur J Obstet Gynecol
Reprod Biol 1995, 62:217-219.
23. Root RK, Dale DC: Granulocyte Colony-Stimulating Factor
and Granulocyte-Macrophage Colony-Stimulating Factor:
Comparisons and potential for use in the treatment of infec-
tions in nonneutropenic patients. J Infect Dis 1999, 179(Suppl
2):S342-352.
24. Stephan F, Yang K, Tankovic J, Soussy CJ, Dhonneur G, Duvaldestin
P, Brochard L, Brun-Buisson C, Harf A, Delclaux C: Impairment of
polymorphonuclear neutrophil functions precedes nosoco-
mial infections in critically ill patients.  Crit Care Med 2002,
30:315-322.
25. Quezado Z, Parent C, Karzai W, Depietro M, Natanson C, Hammond
W, Danner RL, Cui X, Fitz Y, Banks SM, Gerstenberger E, Eichacker
PQ: Acute G-CSF therapy is not protective during lethal E.
coli  sepsis.  Am J Phsiol Regulatory Integrative Comp Physiol 2001,
281:R1177-R1185.
26. Karzai W, von Specht BU, Parent C, Haberstroh J, Wollersen K,
Natanson C, Banks SM, Eichacker PQ: G-CSF during Esherichia
coli versus Staphylococcus aureus pneumonia in rats has fun-
damentally different and opposite effects. Am J Respir Crit Care
Med 1999, 159:1377-82.
27. Root RK, Lodato RF, Patrick W, Cade JF, Fotheringham N, Milwee S,
Vincent JL, Torres A, Rello J, Nelson S: Pneumonia Sepsis Study
Group. Multicenter, double-blind, placebo-controlled study
of the use of filgrastim in patients hospitalised with pneumo-
nia and severe sepsis. Crit Care Med 2003, 31:367-373.
28. Smith WS, Sumnicht GE, Sharpe RW, Samuelson SD, Nillard FE:
Granulocyte Colony-Stimulating Factor versus placebo in
addition to penicillin G in a randomised blinded study of
Gram-negative pneumonia sepsis: analysis of survival and
multisystem organ failure. Blood 1995, 86:1301-1309.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2334/4/43/prepub